Director Kimberly Park receives 12,500 Corcept (CORT) stock options
Rhea-AI Filing Summary
Corcept Therapeutics director Kimberly Park received a stock option grant for 12,500 shares of common stock. The options were granted on May 21, 2026 with an exercise price of $59.69 per share and expire on May 21, 2036.
The award was reported as a grant or other acquisition and is held directly. Following this transaction, Park holds options covering 12,500 shares. According to the footnote, the options become exercisable in equal monthly installments over a one-year period starting on May 21, 2026, contingent on her continued service on each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Park Kimberly
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 12,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 12,500 shares (Direct)
Footnotes (1)
- F1. Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
Key Figures
Option grant size: 12,500 shares
Exercise price: $59.69 per share
Expiration date: May 21, 2036
+2 more
5 metrics
Option grant size
12,500 shares
Stock options granted May 21, 2026
Exercise price
$59.69 per share
Stock option strike price
Expiration date
May 21, 2036
Option term end date
Underlying shares
12,500 shares
Common stock underlying the options
Vesting schedule
Monthly over one year
From May 21, 2026, subject to continued service
Key Terms
Stock Option (right to buy), exercise price, Grant, award, or other acquisition, derivative securities, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 59.6900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
derivative securities financial
"transaction_type: derivative"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
exercisable ratably financial
"Exercisable ratably in equal installments on each monthly anniversary"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Corcept Therapeutics (CORT) report for Kimberly Park?
Corcept Therapeutics reported a grant of stock options to director Kimberly Park. She received options on 12,500 shares of common stock, awarded on May 21, 2026, as a compensation-related acquisition rather than an open-market stock purchase.
What is the exercise price and expiration date of Kimberly Park’s Corcept options?
Kimberly Park’s stock options have an exercise price of $59.69 per share and an expiration date of May 21, 2036. She can choose to exercise vested portions any time before expiration, consistent with the award’s terms.
How do Kimberly Park’s Corcept stock options vest over time?
The options vest in equal monthly installments over one year starting May 21, 2026. Each monthly vesting date requires Kimberly Park’s continued service, meaning she must remain in her role for options to become exercisable gradually across that period.
Is Kimberly Park’s Corcept transaction a market purchase or a compensation grant?
The transaction is a compensation grant, not a market purchase. It is coded as a grant or award acquisition, with a transaction price of $0.00 and an exercise price of $59.69, reflecting options issued by the company rather than shares bought in the market.
What are Kimberly Park’s Corcept derivative holdings after this Form 4 transaction?
After the reported transaction, Kimberly Park holds stock options for 12,500 underlying shares of Corcept common stock. The filing shows these as directly owned derivative securities, representing her reported option position following the grant.